In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in..."> In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in..."/>
Image of Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer
Bookmark Share

Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer

In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors suggested their treatment superiority. One of the suggested methods is targeted alpha therapy. In this method, alpha radiation delivers energy to cancer cells and the tumor microenvironment while minimizing toxicity to surrounding tissues. In this chapter, the alpha emitter radiopharmaceutical applications in castration-resistant prostate cancer patients were investigated. Hence, we studied the 223Ra and 225Ac α-emitter radiopharmaceuticals application method and distribution of dose throughout human body organs.

Availability

No copy data

Detail Information
Series Title
-
Call Number
-
Publisher
: IntechOpen,.,
Collation
-
Language
English
ISBN/ISSN
978-1-83969-659-6
Classification
-
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Radiopharmaceuticals - Current Research for Better
Specific Detail Info
-
Statement of Responsibility
Other version/related

No other version available

File Attachment
No Data
Comments
You must be logged in to post a comment